Christopher J. Lord

4 ta ish

Breast Cancer Now

1. PARP inhibitors: Synthetic lethality in the clinic

   Christopher J. Lord, Alan Ashworth

   Sharh maqolaOAOchiq kirish20173 iqtibos

   ABIABI:AkademIndex/2026.other.107390

2. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

   Hannah Farmer, Nuala McCabe, Christopher J. Lord +11

   Maqola20052 iqtibos

   ABIABI:AkademIndex/2026.other.107379

3. BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency

   Yuqiao Shen, Farah Rehman, Ying Feng +7

   MaqolaOAOchiq kirish20132 iqtibos

   ABIABI:AkademIndex/2026.other.107384

4. Resistance to therapy caused by intragenic deletion in BRCA2

   Stacey L. Edwards, Rachel Brough, Christopher J. Lord +6

   Maqola20082 iqtibos

   ABIABI:AkademIndex/2026.other.677601